Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, Van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Doerken B, Le Coutre P (2015)
Publication Status: Published
Publication Type: Journal article, Original article
Publication year: 2015
Publisher: Taylor and Francis Ltd
Book Volume: 56
Pages Range: 2105-2113
Journal Issue: 7
DOI: 10.3109/10428194.2014.981175
A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABL1 mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
APA:
Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F.,... Le Coutre, P. (2015). Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. Leukemia & Lymphoma, 56(7), 2105-2113. https://doi.org/10.3109/10428194.2014.981175
MLA:
Kaeda, Jaspal, et al. "Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia." Leukemia & Lymphoma 56.7 (2015): 2105-2113.
BibTeX: Download